9, 10 Brewer9 recently analyzed why vitamin E is ineffective for the treatment of AD, and the reasons, including inappropriate

doses, inappropriate timing, and unbalanced monotherapy in the trials, were presumed. In addition, Steinhubl10 provided several possibilities for the negative trials of vitamin E in atherosclerosis, such as the wrong form of vitamin E (a synthetic form instead of a natural form comprising eight different isoforms used in the trials), inadequate durations, and the wrong patients. All these aspects should be taken into account when rigorous trials of vitamin E in WD are conducted. In addition, the rational suggestions proposed by Lu4 for the antioxidant selleck chemicals llc treatment of chronic liver diseases have important implications for future trials of vitamin E in WD. Liang Shen Ph.D.*, Hong-Fang Ji Ph.D.*, * Shandong Provincial selleck Research Center for Bioinformatic Engineering and Technique, Shandong University of Technology, Zibo, People’s Republic of China. “
“Drug-induced liver injury is one of the more challenging forms of liver disease, both in diagnosis and management. Several hundred drugs, nutritional supplements, and herbal medications have been implicated in causing liver injury. Their clinical presentation can be highly variable and mimic almost any form of liver disease. The literature on drug-induced

liver injury is large, but spread among many journals in many different specialties and languages. Excellent textbooks are available, but they are rapidly out-of-date and not always easily accessed. Drug-induced

liver injury is also a challenging area of research, in that most cases are unpredictable, idiosyncratic, and rare and thus difficult to study. As a consequence, there have been few advances in the understanding, control, or prevention of drug-induced liver injury selleck chemical in the last 50 years. DILIN, Drug-Induced Liver Injury Network; NIDDK, National Institute of Diabetes and Digestive and Kidney Diseases; NLM, National Library of Medicine. As a part of a long-term initiative in promoting basic and clinical research on drug-induced liver injury, the Liver Disease Research Branch of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in collaboration with the National Library of Medicine (NLM) has created the LiverTox website (www.livertox.nih.gov) (Fig. 1). LiverTox is a multilayered, informational, and interactive website with comprehensive and evidence-based information on drug, dietary supplement, and herbal-induced liver injury that is freely accessible to physicians, researchers, and the public. The website is particularly designed for use by physicians and healthcare professionals who might rarely see patients with drug-induced liver injury, including family practitioners, internists, pediatricians, psychiatrists, surgeons, specialists, and subspecialists in all areas of medicine.